Advances in cystic fibrosis (CF) therapy over the last decade have substantially improved lung function and reduced pulmonary exacerbations, particularly for people with CF (pwCF) treated with highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy (HEMT) [1]. The gene discussed is CFTR; the disease is cystic fibrosis.